Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA

被引:3
作者
Heeke, Simon [1 ]
Gandhi, Saumil [2 ]
Tran, Hai T. [1 ]
Lam, Vincent K. [3 ]
Byers, Lauren A. [1 ]
Gibbons, Don L. [1 ]
Gay, Carl M. [1 ]
Altan, Mehmet [1 ]
Antonoff, Mara B. [4 ]
Le, Xiuning [1 ]
Tu, Janet [1 ]
Saad, Maliazurina B. [5 ]
Pek, Michelle [6 ]
Poh, Jonathan [7 ]
Ngeow, Kao Chin [7 ]
Tsao, Anne [1 ]
Cascone, Tina [1 ]
Negrao, Marcelo, V [1 ]
Wu, Jia [1 ,5 ]
Blumenschein Jr, George R. [1 ]
Heymach, John, V [1 ]
Elamin, Yasir Y. [1 ]
机构
[1] UT MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[2] UT MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX USA
[3] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA
[4] UT MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, Houston, TX USA
[5] UT MD Anderson Canc Ctr, Dept Imaging Phys, Houston, TX USA
[6] Lucence Hlth Inc, Palo Alto, CA USA
[7] Lucence Diagnost Pte Ltd, Singapore, Singapore
来源
JTO CLINICAL AND RESEARCH REPORTS | 2025年 / 6卷 / 04期
关键词
ALK; NSCLC; Liquid biopsy; ctRNA; ctDNA; EFFICACY;
D O I
10.1016/j.jtocrr.2025.100795
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Although the administration of tyrosine-kinase inhibitors in ALK-rearranged NSCLC has revolutionized precision medicine, the detection of gene rearrangements from liquid biopsies remains challenging. RNA-based detection has revealed promising sensitivity for rearrangement detection and thus we hypothesize that a liquid biopsy assay analyzing circulating tumor RNA (ctRNA) in addition to circulating tumor DNA (ctDNA) will improve detection. Furthermore, we hypothesize that the detection of gene fusions at baseline will correlate with clinical outcomes. Methods: We retrospectively analyzed 86 plasma samples from 33 patients enrolled in the BRIGHTSTAR clinical trial assessing local consolidative therapy (LCT) and brigatinib in patients with stage IV or recurrent NSCLC and confirmed ALK rearrangement (NCT03707938) using a targeted next- generation sequencing assay that analyzes ctDNA to detect gene rearrangements and mutations in 80 genes and ctRNA to detect gene arrangements in 36 genes. Results: ALK rearrangements were detected in 15 of 28 patients (54%) at baseline, of which eight were detected in both ctDNA and ctRNA. ALK rearrangements were detected in two patients pre-LCT, exclusively in ctRNA, but cleared completely post-LCT. The detection of ALK fusion at baseline was associated with significantly worse progression-free survival (p = 0.033). Plasma cell-free DNA concentrations for patients with detectable ALK rearrangements at baseline were significantly higher than for those without detectable gene fusions (12.3 ng/mL versus 20.2 ng/mL, p = 0.0046). Conclusions: The inclusion of ctRNA in liquid biopsies increased detection of ALK rearrangements and detection at baseline was associated with significantly worse progression- free survival highlighting the added benefit of ctRNA. Copyright (c) 2025 by the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/ licenses/by-nc-nd/4.0/).
引用
收藏
页数:7
相关论文
共 15 条
[1]   Current challenges and best practices for cell-free long RNA biomarker discovery [J].
Cabus, Lluc ;
Lagarde, Julien ;
Curado, Joao ;
Lizano, Esther ;
Perez-Boza, Jennifer .
BIOMARKER RESEARCH, 2022, 10 (01)
[2]  
Chalmers J, 2022, PLoS One, V17
[3]   Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK plus Non-small Cell Lung Cancer in the Global Phase III ALEX Trial [J].
Dziadziuszko, Rafal ;
Peters, Solange ;
Mok, Tony ;
Camidge, D. Ross ;
Gadgeel, Shirish M. ;
Ou, Sai-Hong Ignatius ;
Konopa, Krzysztof ;
Noe, Johannes ;
Nowicka, Malgorzata ;
Bordogna, Walter ;
Morcos, Peter N. ;
Smoljanovic, Vlatka ;
Shaw, Alice T. .
CLINICAL CANCER RESEARCH, 2022, 28 (09) :1800-1808
[4]   Ultrafast Gene Fusion Assessment for Nonsquamous NSCLC [J].
Hofman, Veronique ;
Heeke, Simon ;
Bontoux, Christophe ;
Chalabreysse, Lara ;
Barritault, Marc ;
Bringuier, Pierre Paul ;
Fenouil, Tanguy ;
Benzerdjeb, Nazim ;
Begueret, Hugues ;
Merlio, Jean Philippe ;
Caumont, Charline ;
Piton, Nicolas ;
Sabourin, Jean-Christophe ;
Evrard, Solene ;
Syrykh, Charlotte ;
Vigier, Anna ;
Brousset, Pierre ;
Mazieres, Julien ;
Long-Mira, Elodie ;
Benzaquen, Jonathan ;
Boutros, Jacques ;
Allegra, Maryline ;
Tanga, Virginie ;
Lespinet-Fabre, Virginie ;
Salah, Myriam ;
Bonnetaud, Christelle ;
Bordone, Olivier ;
Lassalle, Sandra ;
Marquette, Charles-Hugo ;
Ilie, Marius ;
Hofman, Paul .
JTO CLINICAL AND RESEARCH REPORTS, 2023, 4 (02)
[5]   ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non-small cell lung cancer [J].
Hou, Helei ;
Sun, Dantong ;
Zhang, Chuantao ;
Liu, Dong ;
Zhang, Xiaochun .
THORACIC CANCER, 2021, 12 (06) :962-969
[6]   Circulating Tumor DNA Enables Sensitive Detection of Actionable Gene Fusions and Rearrangements Across Cancer Types [J].
Kasi, Pashtoon M. ;
Lee, Jessica K. ;
Pasquina, Lincoln W. ;
Decker, Brennan ;
Vanden Borre, Pierre ;
Pavlick, Dean C. ;
Allen, Justin M. ;
Parachoniak, Christine ;
Quintanilha, Julia C. F. ;
Graf, Ryon P. ;
Schrock, Alexa B. ;
Oxnard, Geoffrey R. ;
Lovly, Christine M. ;
Tukachinsky, Hanna ;
Subbiah, Vivek .
CLINICAL CANCER RESEARCH, 2024, 30 (04) :836-848
[7]   Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitors [J].
Kwon, Minsuk ;
Ku, Bo Mi ;
Olsen, Steve ;
Park, Sehhoon ;
Lefterova, Martina ;
Odegaard, Justin ;
Jung, Hyun-Ae ;
Sun, Jong-Mu ;
Lee, Se-Hoon ;
Ahn, Jin Seok ;
Park, Keunchil ;
Ahn, Myung-Ju .
CANCER MEDICINE, 2022, 11 (15) :2944-2956
[8]   Plasma Genotyping From the CROWN, ALTA-1L, and ALEX Trials: Can We Speak With One Voice on What to Test, How to Test, When to Test, and for What Purpose? [J].
Lee, Jii Bum ;
Ou, Sai-Hong Ignatius .
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) :1434-1442
[9]   Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC [J].
Li, Weihua ;
Guo, Lei ;
Liu, Yutao ;
Dong, Lin ;
Yang, Lin ;
Chen, Li ;
Liu, Kaihua ;
Shao, Yang ;
Ying, Jianming .
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) :404-418
[10]   Current opportunities and challenges in ALK-positive lung cancer [J].
Lin, Jessica J. ;
Gainor, Justin F. .
TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (01) :1-4